These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19854838)

  • 21. The FDA black box for EPO: what should nephrologists do?
    Singh AK
    Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
    [No Abstract]   [Full Text] [Related]  

  • 22. Reevaluating erythropoiesis-stimulating agents.
    Kestenbaum B
    N Engl J Med; 2010 May; 362(18):1742; author reply 1743-4. PubMed ID: 20445190
    [No Abstract]   [Full Text] [Related]  

  • 23. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 24. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis.
    van der Meer P; Groenveld HF; Januzzi JL; van Veldhuisen DJ
    Heart; 2009 Aug; 95(16):1309-14. PubMed ID: 19168472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future.
    Goldsmith D
    Nephrol Dial Transplant; 2011 Jan; 26(1):24-8. PubMed ID: 20852072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The KDIGO anemia guideline: can reason triumph over regulation?
    Wish JB
    Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
    [No Abstract]   [Full Text] [Related]  

  • 29. Reevaluating erythropoiesis-stimulating agents.
    Cotter DJ
    N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
    [No Abstract]   [Full Text] [Related]  

  • 30. 2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010?
    Goldsmith D
    Clin J Am Soc Nephrol; 2010 May; 5(5):929-35. PubMed ID: 20413441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 32. The treatment of anemia in chronic kidney disease: understandings in 2006.
    Levin A
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):267-71. PubMed ID: 17420672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of agents to reduce infarct size: it can be quite REVEALing.
    Bhatt DL
    JAMA; 2011 May; 305(18):1908-9. PubMed ID: 21558525
    [No Abstract]   [Full Text] [Related]  

  • 34. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
    Krapf R; Hulter HN
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 37. Erythropoietins should be used according to guidelines.
    Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
    Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
    [No Abstract]   [Full Text] [Related]  

  • 38. Is normalising haemoglobin in patients with CKD harmful and if so, why?
    Littlewood TJ
    J Ren Care; 2009 Dec; 35 Suppl 2():25-8. PubMed ID: 19891682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 40. Reaction from renal associations. Renal Physicians Association.
    Blaser R
    Nephrol News Issues; 2007 May; 21(6):61-2, 64. PubMed ID: 17518126
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.